Status:

COMPLETED

Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome

Lead Sponsor:

Line Cleemann

Collaborating Sponsors:

Novo Nordisk A/S

The County of Frederiksborg

Conditions:

Turner Syndrome

Eligibility:

FEMALE

10-25 years

Phase:

PHASE4

Brief Summary

The purpose of this study is to examine whether a larger dosage of estrogen than the one used today will secure the development of a normal sized uterus and increase the strength of the bones in girls...

Detailed Description

Turner syndrome is a common chromosomal disorder with only one X-chromosome or partial deletions in one X-chromosome in all or some of the cell-lines in the body. Appr. 18 girls/year are being born wi...

Eligibility Criteria

Inclusion

  • Verified Turner syndrome
  • Ages 10-25 years

Exclusion

  • Contraindications to the MR-scan
  • Contraindications to the trial medication
  • Severe or chronic sickness with impact on the parameters of the study or incompatibility with the trial medication
  • Intake of medications with interactions with trial medication

Key Trial Info

Start Date :

June 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2013

Estimated Enrollment :

43 Patients enrolled

Trial Details

Trial ID

NCT00134745

Start Date

June 1 2005

End Date

March 1 2013

Last Update

June 14 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Pediatric Unit, Hillerod Hospital

Hillerød, Frederiksborg County, Denmark, 4300

Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome | DecenTrialz